Tandlægeselskabet Colosseum Sønderborg ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  0.5% 0.5% 0.5% 0.5% 0.5%  
Bankruptcy risk  0.0% 12.8% 2.6% 5.0% 2.6%  
Credit score (0-100)  0 18 60 43 60  
Credit rating  N/A BB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  0.0 1,715 7,967 7,996 9,124  
EBITDA  0.0 -253 1,262 775 1,598  
EBIT  0.0 -409 748 283 1,037  
Pre-tax profit (PTP)  0.0 -445.8 662.1 218.7 1,013.0  
Net earnings  0.0 -445.8 614.1 162.2 727.0  
Pre-tax profit without non-rec. items  0.0 -446 662 219 1,013  

 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 1,558 1,657 1,201 649  
Shareholders equity total  0.0 -406 208 370 767  
Interest-bearing liabilities  0.0 2,070 1,609 0.0 0.0  
Balance sheet total (assets)  0.0 4,134 4,192 2,410 2,433  

Net Debt  0.0 755 152 -192 -34.0  
 
See the entire balance sheet

Volume 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 1,715 7,967 7,996 9,124  
Gross profit growth  0.0% 0.0% 364.4% 0.4% 14.1%  
Employees  0 12 12 12 11  
Employee growth %  0.0% 0.0% 0.0% 0.0% -8.3%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 4,134 4,192 2,410 2,433  
Balance sheet change%  0.0% 0.0% 1.4% -42.5% 1.0%  
Added value  0.0 -253.1 1,262.0 796.6 1,598.3  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 1,402 -415 -949 -1,113  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 -1.0 1.0 2.0 3.0  

Profitability 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% -23.9% 9.4% 3.5% 11.4%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% -8.9% 17.2% 8.7% 43.2%  
ROI %  0.0% -19.5% 38.6% 23.8% 117.0%  
ROE %  0.0% -10.8% 28.3% 56.0% 127.8%  

Solidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.0% -9.0% 5.0% 15.4% 31.6%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% -298.5% 12.0% -24.8% -2.1%  
Gearing %  0.0% -510.2% 772.4% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 4.1% 4.8% 8.4% 0.0%  

Liquidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 0.7 0.8 0.6 1.4  
Current Ratio  0.0 0.8 0.8 0.7 1.4  
Cash and cash equivalent  0.0 1,315.0 1,457.3 192.1 34.0  

Capital use efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 -802.0 -626.8 -546.8 549.9  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 -21 105 66 145  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 -21 105 65 145  
EBIT / employee  0 -34 62 24 94  
Net earnings / employee  0 -37 51 14 66